Glycosylated hemoglobin (HbA~1c~) was proposed as a reliable tool for diagnosing diabetes and identifying subjects at increased risk of type 2 diabetes ([@B1]). In 2010, the American Diabetes Association (ADA) pointed out that prevention strategies should be particularly intensive in subjects with high-normal HbA~1c~ because they have the greatest risk ([@B2]), but this recommendation was based more on common sense than literature data. In fact, only few studies ([@B3],[@B4]) showed an elevated risk of type 2 diabetes in subjects with high-normal HbA~1c~. Moreover, in these studies type 2 diabetes was self-reported during telephone interviews. To support ADA recommendations, we evaluated diabetes risk in the 6.00--6.49% category of HbA~1c~, with a more robust approach based on laboratory measurement of glycemic parameters.

RESEARCH DESIGN AND METHODS {#s5}
===========================

The study was conducted within the framework of the Bruneck Study, a long-term, prospective population-based survey of atherosclerosis and its risk factors carried out in Bruneck (northeastern Italy), with a baseline evaluation in 1990 ([@B5]). Among 1,000 randomly sampled Caucasian men and women aged 40--79 years, 936 volunteered. After excluding the few individuals with incomplete data, those with diabetes at baseline, and the very few lost to follow-up, in the remaining 842 subjects new cases of type 2 diabetes were registered in the follow-up examinations of 1995, 2000, and 2005. The protocol was approved by the ethics committee of the University of Verona. All participants gave an informed consent.

Clinical and biochemical measurements {#s6}
-------------------------------------

Information about medical history, drug use, and lifestyle was collected by a questionnaire. Weight, height, waist and hip circumferences, and blood pressure were measured with standard techniques. At the baseline and follow-up examinations, venous blood was sampled in the morning after an overnight fast for laboratory measurements, including fasting plasma glucose (FPG) and HbA~1c~ (Diabetes Control and Complications Trial--aligned assay; equipment and reagents from BioRad, Milan, Italy, at both baseline and follow-up examinations). At both baseline and follow-up, diabetes was diagnosed when HbA~1c~ was ≥6.5% or diabetes treatment was ongoing. In a parallel analysis, diabetes was diagnosed when FPG was ≥7.0 mmol/L or diabetes treatment was ongoing. Details on parameters examined and analytical procedures were previously reported ([@B5],[@B6]).

Statistical analysis {#s7}
--------------------

Subjects were stratified into four HbA~1c~ categories (\<5.0, 5.00--5.49 \[reference\], 5.50--5.99, and 6.00--6.49%). The HbA~1c~ category 5.00--5.49% had the largest number of participants (*n* = 345) and was used as the reference. Hazard ratios (HRs) for type 2 diabetes in the HbA~1c~ categories were estimated with Cox proportional hazards models. Model 0 was unadjusted. Model 1 included age and sex. Model 2 also included LDL and HDL cholesterol, log-transformed triglycerides, BMI, waist-to-hip ratio, hypertension, family history of diabetes, education, alcohol, physical activity, and smoking. Model 3 included the variables in model 2 plus variables that are abnormal in conditions potentially affecting HbA~1c~ (white blood cell count, hemoglobin, ferritin, and creatinine). Additional models were run with updated variables (HbA~1c~ and other variables were assessed every 5 years during follow-up). In these models, baseline HbA~1c~ predicted diabetes in the first 5-year follow-up period, HbA~1c~ at the 5-year follow-up predicted diabetes in the following 5-year follow-up, and so forth in multivariable equations overcoming the limitations of single measures. In parallel analyses, the same models were run with impaired fasting glucose (IFG) as a risk variable, and diabetes was diagnosed with FPG at baseline and follow-up. All reported *P* values are two-sided.

RESULTS {#s8}
=======

The table shows that incident cases of type 2 diabetes increased across categories of HbA~1c~: approximately one of four subjects from the 6.00--6.49% category (high normal) developed diabetes over 15 years. In this category, type 2 diabetes risk was 13- to 16-fold increased (models 0 and 1). The risk was only slightly reduced after adjusting for several putative confounding factors (models 2 and 3) and was definitely greater when updated variables were included into the models ([Table 1](#T1){ref-type="table"}). Analyses including interaction terms between HbA~1c~ categories and factors that might affect interpretation of HbA~1c~ (i.e., white blood cell count, hemoglobin, ferritin, and creatinine) did not yield evidence of differential associations according to HbA~1c~ level, supporting the lack of effect modification.

###### 

HRs for 15-year incidence of type 2 diabetes according to HbA~1c~

                                 HbA~1c~ category                                                                                                               
  ------------------------------ --------------------------------------------------------------------------------- ---------------------- --------------------- ----------------------
  *n*                            112                                                                               345                    315                   70
  Cases of incident diabetes     3                                                                                 9                      31                    20
  Cases per 1,000 person-years   1.9                                                                               1.9                    7.8                   25.8
                                 HRs (95% CIs) in models with baseline variables[\*](#t1n1){ref-type="table-fn"}                                                
  Model 0                        Model 1                                                                           Model 2                Model 3               
  HbA~1c~ category                                                                                                                                              
   \<5.00%                       1.00 (0.27--3.68)                                                                 1.11 (0.30--4.14)      1.18 (0.31--4.41)     1.27 (0.34--4.79)
   5.00--5.49% (reference)       1.00                                                                              1.00                   1.00                  1.00
   5.50--5.99%                   4.30 (2.05--9.03)                                                                 3.79 (1.79--8.06)      3.24 (1.50--6.98)     3.21 (1.49--6.92)
   6.00--6.49%                   15.67 (7.13--34.47)                                                               12.50 (5.51--28.34)    9.74 (4.21--22.56)    9.26 (4.01--21.40)
  * P* value for trend           \<0.001                                                                           \<0.001                \<0.001               \<0.001
  HbA~1c~ (per 1% increase)      11.00 (5.66--21.39)                                                               8.54 (4.21--17.31)     6.08 (2.96--12.47)    6.05 (2.90--12.60)
                                 HRs (95% CIs) in models with updated variables[†](#t1n2){ref-type="table-fn"}                                                  
  Model 0                        Model 1                                                                           Model 2                Model 3               
  HbA~1c~ category                                                                                                                                              
   \<5.00%                       2.31 (0.39--13.92)                                                                2.55 (0.42--15.39)     2.55 (0.42--15.58)    2.43 (0.40--14.97)
   5.00--5.49% (reference)       1.00                                                                              1.00                   1.00                  1.00
   5.50--5.99                    12.58 (3.83--41.30)                                                               11.62 (3.52--38.36)    10.97 (3.30--36.47)   11.43 (3.43--38.07)
   6.00--6.49%                   61.05 (18.23--204.4)                                                              52.82 (15.57--179.3)   45.52 (13.1--158.0)   46.72 (13.4--163.3)
  * P* value for trend           \<0.001                                                                           \<0.001                \<0.001               \<0.001
   HbA~1c~ (per 1% increase)     41.37 (18.79--91.07)                                                              36.82 (16.30--83.21)   31.10 (13.31--72.7)   32.24 (13.60--76.41)

Model 0 was unadjusted. Model 1 included age and sex. Model 2 included the variables in model 1 plus LDL and HDL cholesterol levels, log-transformed triglyceride levels, BMI, waist-to-hip ratio, hypertension, family history of diabetes, education, alcohol use, physical activity score, and smoking status. Model 3 included all variables in model 2 plus white blood cell count, hemoglobin, ferritin, and creatinine.

\*Cox models in which HbA~1c~ and other variables at baseline were used to predict diabetes in the 15-year follow-up.

†Cox models in which updated HbA~1c~ and other variables were used to predict diabetes in subsequent 5-year follow-up periods (see text for details).

In parallel analyses in which diabetes was diagnosed at both baseline and follow-up with FPG, and in which subjects at risk were those in the IFG category, we found that the latter conferred an increased diabetes risk (HRs \[95% CIs\] in subjects with IFG vs. normal FPG \[\<5.55 mmol/L\]: 8.20 \[4.66--14.40\], 7.72 \[4.36--13.66\], 5.83 \[3.23--10.54\], and 5.92 \[3.24--10.80\] in the four models, respectively). These models included the same variables as those focusing on HbA~1c~. However, diabetes risk in subjects with IFG was substantially lower than in subjects with high-normal HbA~1c~.

CONCLUSIONS {#s9}
===========

It is well known that HbA~1c~ captures chronic hyperglycemia in the prior 2--3 months, is well correlated to chronic diabetes complications, and has less preanalytical problems and biological variability than plasma glucose, with a noninferior standardization ([@B7]). For such reasons, HbA~1c~ was recommended for diabetes diagnosis and risk stratification ([@B1],[@B2]).

The findings of the current study confirm a progressively increased risk of type 2 diabetes across categories of HbA~1c~ and clearly document that subjects with high-normal HbA~1c~ have a strong risk of developing type 2 diabetes, even after adjusting for several putative risk factors (e.g., BMI) and potentially confounding variables (e.g., anemia). Remarkably, diabetes risk in subjects with high-normal HbA~1c~ is higher than in subjects with IFG.

Noteworthy, our study population was entirely Caucasian, and subjects were aged \>40 years. Therefore, our findings cannot be necessarily extrapolated to other ethnicities and/or to younger subjects.

To the best of our knowledge, this study is the first to examine how baseline HbA~1c~ predicts HbA~1c~-diagnosed diabetes. Our findings, which are consistent with those of studies based on self-reported diagnosis of diabetes ([@B3],[@B4]), more strongly support the ADA recommendations of using HbA~1c~ for diabetes risk stratification and including subjects with high-normal levels in an effective prevention strategy. These subjects, indeed, have a high rate of progression to diabetes and deserve particular attention in order to prevent or delay the disease. Specific intervention trials, however, are needed to confirm such a conclusion because those conducted so far, based on lifestyle changes and/or drug use, recruited subjects at risk according to their plasma glucose levels and not HbA~1c~.
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